.

What's Hot in Workers' Comp

TOP 10 DEVELOPMENTS IN DELAWARE WORKERS’ COMPENSATION IN 2022

What’s Hot in Workers’ Comp, Vol. 26, No. 12, December 2022

December 1, 2022

by Benjamin K. Durstein

1.    The General Assembly amended Section 2347 of the Workers’ Compensation Act regarding Petitions for Review to codify existing litigation practices and clarify areas of dispute.

The Bill was signed into law by Governor Carney on October 7, 2022. The language is completely re-worked from the prior version. There are multiple changes, including, but not limited to: 
•    PFR hearings may not occur within 26 weeks of each other;
•    Supporting documentation is now required to accompany a PFR filing;
•    A PFR may now be filed to determine entitlement to permanency benefits;
•    PFR service may now be accomplished electronically and by private mailing services; and 
•    Workers’ Compensation Fund participation and reimbursement rights were clarified.

2.    New workers’ compensation rates.

The Department of Labor announced that the new workers’ compensation rates effective July 1, 2022, establish an average weekly wage of $1,234.04. Accordingly, the maximum weekly compensation rate is $822.70 and the minimum weekly compensation rate is $274.24.

3.    Statistics from the Department of Labor.

The 24th Annual Report from the Department of Labor is available on the state’s website and provides updates, data and information that cover the year 2021. Of note, Utilization Review requests increased from 2020, and approximately 62% resulted in an appeal to the Industrial Accident Board, although most appeals were withdrawn before hearing. Chronic pain treatment continues to represent the most challenged treatment modality. There are now 3,364 certified providers in Delaware, which represents a 19% increase from 2020. Five-year cumulative statistics on appeals indicates the Board has rendered 1,594 decisions, 202 of which were appealed. Sixty-four decisions were affirmed, 26 were reversed or remanded, 87 were dismissed or withdrawn, and 25 were pending decision at the time of the report. Accordingly, 14.7% of decided appeals in the last five years were reversed and/or remanded.

4.    The Superior Court reversed and remanded a Board decision that denied a petition for a COVID-19 workplace exposure.
Carl Fowler v. Perdue Farms, Inc., 2022 WL 807327 (Del. Super. March 16, 2022)

The claimant alleged that he suffered a compensable COVID-19 exposure at work. Although both medical experts concluded the COVID-19 condition was likely acquired at work, the Industrial Accident Board denied the petition because it did not find the claimant’s testimony about other potential exposures or histories provided to the doctors to be credible. The claimant appealed.

The Superior Court reversed and remanded the decision because the Board had rejected unrebutted medical expert testimony and had improperly relied on its own expertise and extrajudicial knowledge of facts not in the record. Additionally, the Board committed legal error and imposed an incorrect burden of proof. The court felt that the claimant was effectively tasked with proving the workplace exposure beyond a reasonable doubt rather than the correct “more likely than not” standard. The case was remanded for further proceedings and instructed to determine whether or not COVID-19 is an occupational disease if exposure was proved. The remand hearing has not yet occurred.

5.    The Industrial Accident Board denied two COVID-19 exposure petitions.
Cacchioli v. Infinity Consulting Solutions, (IAB No. 1501061 - Decided March 9, 2022) and Hudson v. Beebe Medical Center, IAB No, 1516467 (Decided Oct. 24, 2022).

In Cacchioli, the claimant filed a lawsuit in Superior Court for wrongful conduct by the employer that resulted in COVID exposure at work and, ultimately, the claimant’s death. The court stayed the lawsuit in order to have the Industrial Accident Board determine whether it had exclusive jurisdiction over the claim and, more specifically, whether COVID qualified as an occupational disease under the Workers’ Compensation Act.

At the hearing before the Board, the claimant argued that his own petition should be dismissed for lack of jurisdiction. The Board agreed and reasoned that “in the limited office setting described in the petition in this case, there is no assertion that claimant’s occupation produced a hazard of contracting COVID-19 distinct from and greater than the hazard attending employment in general.” However, the Board further found that COVID-19 “can certainly be a compensable occupational disease in a proper situation.”

In Hudson, the Board denied a petition from a nurse who worked in the “COVID unit” of a hospital for failure to meet burden to prove COVID-19 was contracted at work and failure to prove that any alleged exposure qualified as an occupational disease for purposes of workers’ compensation under the specific circumstances of her employment. The decision is on appeal.

6.    The Supreme Court affirmed a decision of the Board that determined a claimant failed to meet his burden to prove a permanent impairment even though it did not accept the opinions of the employer’s medical expert.
Shipmon v. State of Delaware, 275 A.3d 755 (Table), 2022 WL 984396 (Del. April 1, 2022)

The claimant alleged that he sustained a 22% cervical spine permanent impairment as a result of the work accident based on the opinions of Dr. Stephen Rodgers. In defense, the employer relied on the opinions of Dr. Stephen Fedder, who testified that there was no permanent impairment caused by the work accident. Following a hearing, the Industrial Accident Board concluded the claimant failed to meet his burden to prove that he sustained a permanent impairment of his neck. The Board commented that, although it did not believe the claimant had a zero percent rating, it would not award permanency benefits because Dr. Rodgers’ testimony failed to carry the burden to prove his 22% rating. The Superior Court affirmed the Board’s decision.

The Supreme Court rejected the claimant’s argument that the Board erred as a matter of law when it declined to award him permanent impairment benefits while simultaneously finding that he “suffered permanent limited function.” The court reasoned that the Board is permitted to unilaterally assign a specific degree of permanent partial impairment in the absence of any supporting evidence and that the Board “should not . . . make a determination that a permanent partial impairment is of a certain degree when there is no evidence in the record to support that finding.” The judgment of the Superior Court was affirmed.

7.    The Supreme Court held that an employer may challenge medical treatment via a Petition for Review instead of Utilization Review if causation is disputed, despite a prior UR and and more than eight years’ of paid medical bills for the same treatment.
Sheppard v. Allen Family Foods, 279 A.3d 816 (Del. 2022)

The employer filed a Petition for Review seeking to terminate the claimant’s entitlement to ongoing narcotic pain medications on the basis that they were not reasonable, necessary or causally related to a 2011 work accident. The claimant moved to dismiss the petition when the employer completed its case-in-chef because the employer had failed to raise a good faith causation defense and, therefore, the treatment was required to be referred to Utilization Review. The Industrial Accident Board concluded that the employer presented sufficient evidence on the issue of causation to proceed via Petition for Review and denied the motion. The Superior Court affirmed.

The Supreme Court opined that the employer’s medical expert testimony was sufficient to raise an issue of causation and the employer was not precluded from making that argument now. The prior Utilization Review referral did not forever bar an employer from raising a causation, and the employer’s payments through September 4, 2019, did not equate to a waiver of causation with respect to the Petition for Review. Lastly, the court emphasized that there was a good faith basis for the causation argument as the claimant and her medical expert were both determined to be less credible than employer’s expert.

8.    The Superior Court holds that § 2322(b) was not superseded by the adoption of § 2322B and that when an employer refuses to furnish medical treatment, claimants are entitled to recover the “reasonable cost” of medical treatment instead of the Delaware Fee Schedule amount.
Quaile v. National Tire and Battery, 2022 WL 2527619 (Del. Super. July 7, 2022)

The employer denied medical treatment for a rectal and left knee injury. The claimant filed a petition, and the Board determined those injuries were compensable. The employer was ordered to pay medical expenses according to the Delaware Fee Schedule. The claimant appealed and contended that he was entitled to more than the Fee Schedule. Following a remand and another appeal, the issue made it to the Superior Court.

The court determined that the plain language of the statute did not address or control the issues, so the language must be interpreted to ensure that the overriding, benevolent purpose of the Workers’ Compensation Act was achieved. It concluded that Section 2322(b) was not rendered non-viable by the adoption of Section 2322B. Therefore, because the employer had refused to pay for the treatment expenses at issue, Section 2322(b) determined the appropriate recovery amount instead of the Fee Schedule amount and the claimant was entitled to recover the “reasonable cost” of the treatment. The “reasonable cost” was held to be the outstanding balance with the providers of $16,818.86, following payment/adjustments from health insurance.

9.    The Board denied a claimant’s petition for increased medical bill payments for ketamine infusions under the theory that the Delaware Fee Schedule did not apply and the Board should order payment of the “reasonable cost” of the treatment.” 
Taylor v. State of Delaware, (IAB No. 1447456) (September 6, 2022)

The claimant was injured in a compensable work accident on September 16, 2016, and subsequently developed Complex Regional Pain Syndrome (CRPS). Beginning in 2017, she regularly received ketamine infusion procedures from a surgery center in Pennsylvania as part of her treatment plan. The amount billed by the surgery center for each infusion was $8,700. The State of Delaware (the employer) initially paid a higher amount but subsequently corrected the reimbursement to around $547 per the Delaware Fee Schedule. The charge versus payment disparity prompted the claimant to file a petition to determine whether the employer was paying the correct amount.

The Industrial Accident Board held that 19 Del. C. § 2322B(7) applied because the surgery center was an out-of-state provider not licensed in Delaware or certified under the Delaware workers’ compensation payment system. The Delaware Fee Schedule was the appropriate mechanism to determine the payment. The Board rejected the claimant’s argument that the “reasonable cost” provision of 19 Del. C. § 2322(b) applied pursuant to the Quaile v. National Tire and Battery decision (summarized above). The Board reasoned that this was not refused or contested treatment because the employer had made payments and agreed to the compensability. The Board explained that the proper forum to obtain a higher rate for ketamine infusions was the Workers’ Compensation Oversight panel established pursuant to the Delaware Workers’ Compensation Act. The petition was denied. The Industrial Accident Board’s decision is currently on appeal to the Superior Court. 

10.    The Delaware Supreme Court held that a lapse in a Delaware doctor’s provider certification renders the treatment not compensable as a matter of law without preauthorization.
Wilson v. Gingerich Concrete & Masonry, 2022 WL 4678846, --- A.3d --- (Del. October 3, 2022)

The claimant injured his cervical spine in a work accident on August 1, 2002. He came under the care of Dr. Bikash Bose in 2014. On July 22019, Dr. Bose performed a cervical fusion surgery that was acknowledged as compensable and paid for by the employer/carrier. When the fusion did not heal in a timely fashion, Dr. Bose performed a second sugary on February 22, 2021. The employer disputed the compensability of the second surgery, and the claimant filed a petition. It was determined that Dr. Bose’s certification as a workers’ compensation provider per 19 Del. C. § 2322D had lapsed at the time of the second surgery. Although this was claimed to be an “administrative error” resulting from the COVID-19 pandemic, the Industrial Accident Board concluded that certification was mandatory and uncertified treatment was not compensable without preauthorization.

On appeal, the Superior Court affirmed the Board’s decision and rejected the claimant’s argument that a lapse in certification should be treated differently from a lack of certification on the part of a provider. The exceptions in Section 2322D are explicit and do not include a “good faith” exception. The claimant appealed again to the Supreme Court.

The Supreme Court declined to follow prior decisions of the Board that allowed for a “de minimus” exception for Delaware providers who had certification lapses. Any exceptions needed to be crafted by the General Assembly, not the courts. The claimant’s final contention, that he will potentially be liable for the surgery bills through no fault of his own, was not ripe for a decision.

 

What’s Hot in Workers’ Comp, Vol. 26, No. 12, December 2022 is prepared by Marshall Dennehey to provide information on recent legal developments of interest to our readers. This publication is not intended to provide legal advice for a specific situation or to create an attorney-client relationship. We would be pleased to provide such legal assistance as you require on these and other subjects when called upon. ATTORNEY ADVERTISING pursuant to New York RPC 7.1 Copyright © 2022 Marshall Dennehey Warner Coleman & Goggin, all rights reserved. No part of this publication may be reprinted without the express written permission of our firm. For reprints or inquiries, or if you wish to be removed from this mailing list, contact tamontemuro@mdwcg.com.

Firm Highlights

Thought Leadership

Casual Care, Serious Consequences: How Informal Prescribing Can Trigger Medical Board Scrutiny

The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Consider the following scenario: in December 2025, a medical provider renewed a prescription for a long-standing telemedicine patient receiving a Schedule II controlled dangerous substance. This was not a violation of the New Jersey Administrative Code. Another provider doing the same action for an equally situated patient in March 2026 would be in violation. The casual prescriber who is not aware of newer regulatory requirements may have a more difficult time responding to a medical board complaint. Medicine is a highly-regulated helping profession. Without addressing the merits of this regulatory burden, the practice of medicine continues to see drastic changes impacting the everyday life of patient and provider. Telemedicine, COVID-19, and other advances and roadblocks, present a challenge to those saving lives while attempting to comply with the rules of practice. Physicians often discover—through real cases and the lens of regulatory expectations—that even well-intentioned informal help can be reinterpreted as stepping outside mandated professional boundaries, and seemingly harmless actions can be construed as deviations from required practice standards specifically outlined in Title 13, Chapter 35, Subchapters 7.1A of the New Jersey Administrative Code. Title 45, "Professions and Occupations," of the New Jersey code governs the practice of medicine, nursing, optometry, pharmacy, and many other professional occupations. Section 9 specifically addresses the state board of medical examiners and allows for the creation of rules and regulations in Section 45:9-5.3. These regulations can be found in the New Jersey Administrative Code Title 13, Chapter 35. While broad in scope, Chapter 35 contains a subchapter dedicated to the administration and dispensing of prescription drugs. Such knowledge will arm physicians with the tools they need to prevent a negative outcome if a medical board complaint is filed. Likewise, attorneys must be familiar with these regulatory requirements when advising and defending providers. In New Jersey, N.J.A.C. Section 13:35-7.1A(a) requires that a practitioner conduct an examination and appropriately document the same within the medical record before dispensing drugs or issuing prescriptions. The examination must include an "appropriate history and physical examination," a diagnosis based upon the examination and any testing consistent with good medical care, the formulation of a therapeutic plan discussed with the patient, and the availability of appropriate follow-up care. There are only six exceptions to this requirement: In admission orders for a newly hospitalized patient For a patient of another physician for whom the practitioner is taking calls For continuation medications on a short-term basis for a new patient prior to the patient's first appointment For an established patient who, based on sound medical practice, the physician believes does not require a new examination before issuing a new prescription For a patient examined by a healthcare professional who is in collaborative practice with the practitioner When treatment is provided by a practitioner for an emergency medical condition Emergencies are also limited to situations where someone's health is in serious jeopardy, there is serious impairment to bodily functions, or serious dysfunction of any bodily organ or part. During the COVID-19 pandemic, then New Jersey Governor Phil Murphy issued an executive order declaring a public health emergency and a state of emergency that allowed authorized prescribers to prescribe Schedule II controlled dangerous substances via telemedicine. The order was terminated when he left office earlier this year and the state reverted to the requirement of an initial in-person examination and quarterly in-person visits. With this return to prior regulatory requirements, practitioners subject to the jurisdiction of the board of medical examiners may benefit from a refresher on the regulatory limitations on their practice now that the pandemic-era flexibilities have ended. This new requirement may create confusion for prescribers and lead to casual prescribing of medication in violation of the regulations, even in the setting of recurrent telemedicine appointments as noted in the example above. Casual prescribing can take many forms: filling a prescription request from a friend or family member without an examination or contemporary medical record; using telemedicine to expand your practice without proper in-person appointments or documentation in the medical record; failing to ensure appropriate follow-up care for a "one time" prescription; etc. Although not all board complaints end in a publicly available opinion, serious deviations from regulatory requirements can shine a light on practices that will require action by the board if a complaint is received. Consider the following cases: In October 2025, the board issued a final consent order in an administrative action where a doctor provided opioids without examination and his license was permanently revoked. In re Robert Dela Gente, D.O., N.J. State Bd. of Med. Exam'rs Oct. 21, 2025. Criminal charges were filed (though that is not always the case). In a September 2025 consent order, a physician was reprimanded for "prescribing opioids several months in advance without the proper patient follow-up..." and explained that they did so for "patients who can not pay for multiple visits to refill medications." In re A/an E. Schultz, M.D., N.J. State Bd. of Med. Exam'rs Sept. 25, 2025. Another physician was suspended and placed on probation in a consent order for prescribing three patients the weight-loss medication "Ozempic" via text messages through a website called "Push Health" and without any further communication with the patients or taking a medical history. In re Laura E. Purdy, M.D., N.J. State Bd. of Med. Exam'rs Aug. 29, 2025. A June 2025 interim consent order required a "full evaluation and assessment of [a physician's] general knowledge and skill, with specific emphasis on his knowledge of and ability to safely prescribe [controlled dangerous substances]" due to his failure to review a patient's prior medical history and medical record, assess and review the prescription monitoring program before prescribing CDS, and conduct random urine screens on a patient that tested positive for CDS upon admission to his practice because "he trusted the patient." In re Donald Oh, M.D., N.J. State Bd. of Med. Exam'rs June 2, 2025. Each of these examples demonstrate a failure to follow strict procedure regardless of the intention. Failing to follow procedure secondary to good intentions, such as considering a patient's financial constraints, trust in the patient, or utilizing a new telemedicine service platform, will not be a defense to a board complaint. Especially when practicing via telemedicine, practitioners must ensure they are adhering to the appropriate regulatory standard. A provider who calls in a prescription for a traveling friend or family member or agrees to prescribe medication for individuals using the newest phone app will have a hard time meeting the requirements of N.J.A.C. Section 13:35-7.1A. Even if a history was taken, a "therapeutic plan" was created, and "follow up care" was provided, the prescriber would still not be in compliance with the regulation without an in-person examination. In our opening hypothetical, the prescriber's behavior did not change between December and March; however, the legal shift in the regulatory landscape made once acceptable behavior a violation as a required examination did not occur. When complaints are made with regard to informal prescribing, the board has discretion to employ measures to encourage compliance in lieu of formal proceedings such as a private, written warning; suspending fines subject to continuing compliance; medical or professional treatment as may be necessary; medical or diagnostic testing and monitoring; skills assessment; corrective training; participation in outreach programming; or contribution to the consumer fraud protection fund. The lesson for health care practitioners is that regular review of the regulatory requirements can ensure compliance and that casual prescribing may be in violation of state regulations if the necessary components are not met. Even compliant providers who had not conducted an in-person examination for telemedicine patients during the COVID-19 emergency would be in violation of the regulations as of January 2026 for the same practice. Practitioners should be diligent in adhering to the prescribing rules to avoid sanctions related to casual care. Likewise, attorneys advising or defending practitioners before the board must be aware of the in-person examination requirements for prescribing in New Jersey whether the care in question took place in-person or in a telemedicine setting. Reprinted with permission from the April 22, 2026 issue of the New Jersey Law Journal. ©2026 ALM Media Properties, LLC. Further duplication without permission is prohibited. All rights reserved.

Result

No-Cause Jury Verdict Secured in Wrongful Death Trial

We successfully obtained a no-cause jury verdict in a 13-day wrongful death trial. The decedent, a 59-year-old man, was admitted to the emergency room on February 15, 2019, with complaints of abdominal pain, decreased appetite, and constipation, despite the use of laxatives. The patient did not complain of any nausea, vomiting, or diarrhea. He had a significant medical history including diabetes, hypertension, prior coronary artery stenting, morbid obesity (with past gastric bypass surgery), longstanding ventral hernia, and back pain. A CT scan revealed multiple hernias and a potential closed-loop bowel obstruction, leading to a surgery consultation. Our client, an emergency general surgeon, interpreted that the patient did not have a closed loop or any significant obstruction and recommended non-surgical management. The patient was approved to have clear liquids, and had a vomiting incident shortly after, but our client was not notified. The patient was returned to NPO status, and after improving overnight, he was returned to “clears” and additional medical and renal consults were ordered. Our client did not receive any communications from the residents/nurses of any changes in the patient’s condition. On February 18, 2019, two rapid responses were called due to increased heart rate and vomiting. It is believed that the vomiting resulted in aspiration, causing sepsis, ultimately leading to the patient’s death. During the trial, the plaintiff’s sole medical expert highlighted imaging on the wrong hernia, which called into question all of his opinions in the case. We made key objections related to the expert testimony, limiting what the allegations were, and preventing new allegations from being made. After approximately two and a half hours of deliberating, the jury returned a no-cause verdict. 

Thought Leadership

SIDEBAR: News and Happenings

We are pleased to share that attorneys from our health care team have been selected to the 2026  New Jersey and Pennsylvania Super Lawyers and Rising Stars lists. Their dedication to clients and commitment to high-quality work continues to strengthen our firm! Please join us in congratulating: NJ Super Lawyers: Robert T. Evers and Justin F. Johnson NJ Super Lawyer Rising Stars: Nataliana A. Guida  2026 Pennsylvania Super Lawyers: Alyson J. Kirleis and Gary M. Samms 2026 Pennsylvania Rising Stars: Holli K. Archer and Daniel Dolente Victoria Scanlon (Scranton) was a faculty presenter at the 2026 American Roentgen Ray Society (ARRS) Annual Meeting in Pittsburgh. She participated in the “Resident Symposium: Producing Quality Reports,” focusing her presentation on “How to Write a Great Report: Malpractice Lawyer’s Perspective.” Vicky, the only attorney presenter for this two-hour segment, was joined by several health care professionals including diagnostic radiologists, an interventional radiologist, an internal medicine physician, and a radiologist turned AI entrepreneur expert.  Matthew Keris (Scranton), President of the Pennsylvania Association for Health Care Risk Management (PAHCRM) and shareholder in our Scranton Health Care Department, presented an important and timely session titled “Keynote Address: A Conversation with RaDonda Vaught on Criminalizing Errors” at PAHCRM’s Annual Meeting in April. RaDonda is a former Tennessee nurse widely known for being criminally convicted in 2022 of negligent homicide and gross neglect after a 2017 fatal medication error at Vanderbilt University Medical Center. Her case gained national attention because she was criminally prosecuted rather than just facing licensing board action, sparking debate over blaming individual nurses for systemic healthcare failures. Matt and RaDonda’s conversation explored one of the most consequential issues in health care risk management today—how systems respond to human error, and what it means for patient safety, accountability, and the professionals who serve on the front lines. Gary Samms was a panelist for a podcast hosted by the Medical Liability Monitor, “From Outliers to Pattern: The Increasing Predictability of Megaverdicts in the Med-Mal Industry – and How to Reduce the Likelihood of Getting Hit with One.” Gary discussed the changing megaverdict landscape and why “outlier” verdicts are becoming structural, in addition to how plaintiffs turn weaknesses into megaverdicts (including building emotional narrative and jury psychology). Thank you to our clients who joined us for our Trends in Health Care & Health Law seminar on May 14. Led by our Health Care Department Director and Assistant Director, Robin Snyder and Donna Modestine, the session explored key issues that are currently shaping outcomes in health care litigation. We owe a debt of gratitude to our esteemed guest speaker, Mary Ellen Nepps, Esq., Senior Counsel, University of Pennsylvania, who presented “Medical Malpractice Litigation: Driving Another Health Care Crisis in Pennsylvania.” And special thanks to our attorneys who presented and shared their insights, including John J. Hare and Holli Archer who discussed “Highlights in PA Medical Malpractice Law;” David Drake for his presentation, “From Claims to Courtroom: Key Trends in NJ Medical Malpractice Litigation;” and Matthew Keris with an “Update on Health Care Tech Discovery.” Thank you to all of our clients for entrusting us with your health care litigation. We are proud to partner with you as we defend your interests and navigate legal landscapes together.

News

Marshall Dennehey’s John J. Hare Brings Home Attorney of the Year Honors; Firm Named Litigation Department of the Year in Two Categories

Marshall Dennehey took home top honors in three categories at the The Legal Intelligencer’s 2026 Pennsylvania Legal Awards, held June 11 in Philadelphia. The first place awards include: Attorney of the Year: John J. Hare, Chair of the firm’s Appellate Advocacy & Post-Trial Practice Group and Executive Committee member, together with Charles “Chip” Becker of Kline & Specter Litigation Department of the Year, Appellate – Third Win in a Row! Litigation Department of the Year, Product Liability/Mass Torts “There is no one more deserving of Attorney of the Year honors than John. This award is a testament to his exceptional skill, dedication, and leadership—qualities that truly exemplify the very best of our firm,” said G. Mark Thompson, Marshall Dennehey’s President & CEO. “These honors also reflect the strength and depth of our product liability, mass torts, and appellate practices across Pennsylvania and beyond, underscoring our ongoing commitment to delivering outstanding results for our clients.” Attorney of the Year – John J. Hare, Marshall Dennehey, together with Charles “Chip” Becker, Kline & Specter Over the past year, John and Charles were opposing counsel in many of the highest-profile civil appeals in Pennsylvania. John is renowned as a preeminent appellate lawyer on the defense side, and Chip on the plaintiff's side. They have opposed each other repeatedly, exhibiting peerless professionalism and exceptional civility, while zealously litigating under the unremitting pressure of high-profile litigation and record-setting verdicts totaling more than $3.5 billion. They have also collaborated, outside of litigation, on many commissions, committees, and projects of importance to the Pennsylvania judiciary and legal community. Litigation Department of the Year – Appellate Law, Winner (previous winner, 2025 and 2024) 2025 was another standout year for the firm’s Appellate Advocacy & Post‑Trial Practice Group, led by John J. Hare, which was retained to challenge many of Pennsylvania’s “nuclear” verdicts—awards exceeding $10 million. Notably, the department persuaded the Pennsylvania Superior Court to reverse a Philadelphia judgment of $1.09 billion, the largest judgment ever overturned by a Pennsylvania appellate court. The group’s 11 full‑time Pennsylvania‑based appellate lawyers are at the center of Pennsylvania’s most high-profile matters, bringing more than 150 years of combined appellate experience. They routinely handle post‑trial and appellate matters and are frequently engaged to participate in and monitor trials in high‑exposure cases to ensure that critical legal issues are properly raised and preserved for appeal. Litigation Department of the Year – Product Liability/Mass Torts, Winner This marks the first win for the firm’s Pennsylvania Product Liability and Mass Torts practices, which operate within our Casualty Department, managed by Matthew Schorr and Jeff Rapattoni. For almost five decades, Fortune 500 product manufacturers/distributors and their insurers have turned to these groups to defend their litigation. Led by Bradley D. Remick and Vlada Tasich, our Product Liability group’s success can be attributed to its commitment to keeping abreast of ever-changing legal theories, judicial viewpoints, and evolving technology impacting the product liability landscape. Our attorneys have successfully handled thousands of product liability matters in all jurisdictions across the state. Likewise, our mass tort litigation practice – divided into Asbestos & Mass Tort, and Environmental & Toxic Tort Litigation –  has defended manufacturers, distributors, contractors, and premises owners in thousands of personal injury and other claims. Led by Kevin E. Hexstall and Patrick T. Reilly, most attorneys in these groups have more than 20 years of experience, and our seasoned trial team has tried hundreds of cases to verdict, consistently achieving strong results through both trials and settlements. In addition to these awards, Marshall Dennehey was a Litigation Department of the Year finalist for Professional Liability.